Takeda: Primary Immunodeficiency Diseases trials

The registry lists 24 Primary Immunodeficiency Diseases studies with Takeda as lead sponsor. 3 are open to participants now and 12 have results posted.

Phase 1 1Phase 2 7Phase 3 14Phase 4 2No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of TAK-664 in People With Primary Immunodeficiency Diseases Who Have Not Yet Been Treated With ImmunoglobulinsNot yet recruitingNCT07794735Phase 4
• Expanded Access to TAK-881 for People With Primary Immunodeficiency Diseases in the USA and Czech RepublicAvailableNCT06955793
• A Database Survey to Evaluate the Safety of Immune Globulin Subcutaneous (Human), 20% Solution in Participants With Primary ImmunodeficiencyRecruitingNCT06565078
• A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency DiseasesCompletedNCT05755035Phase 2/3Results posted
• A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) ParticipantsCompletedNCT05513586Phase 3Results posted
• A Study of TAK-771 in Japanese People With Primary Immunodeficiency Diseases (PID)CompletedNCT05150340Phase 3Results posted
• An Extension Study of TAK-664 for Japanese People With Primary Immunodeficiency DiseaseCompletedNCT04842643Phase 3Results posted
• A Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Japanese Participants With Primary Immunodeficiency Diseases (PID)CompletedNCT04346108Phase 3Results posted
• Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD SubjectsCompletedNCT03277313Phase 3Results posted
• Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric PIDD SubjectsCompletedNCT03116347Phase 4Results posted
• Tolerability and Safety of IGI, 10% With rHuPH20 in PIDDCompletedNCT01485796Phase 2/3Results posted
• Phase 2/3 Study of IGSC, 20% in PIDDCompletedNCT01218438Phase 2/3Results posted
• Tolerability and Safety of Immune Globulin Subcutaneous Solution (IGSC) and rHuPH20 in PIDCompletedNCT01175213Phase 3Results posted
• Gammagard Liquid and rHuPH20 in PIDCompletedNCT00814320Phase 3Results posted
• Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) SubjectsCompletedNCT00546871Phase 2/3Results posted
• At-Home Subcutaneous Immunoglobulin Replacement Therapy Using Alexa SkillCompletedNCT06150534
• A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency DiseasesActive, not recruitingNCT06076642Phase 3
• Retrospective, Observational Chart Review Study Conducted in Poland to Document the Management and Clinical Outcome of CUVITRU and HYQVIA in Pediatric Participants (< 18 Years) With Primary Immunodeficiency (PID)CompletedNCT04636502
• Real-world CANadian CUvitru Non-Interventional Study in Subjects Transitioning From Subcutaneous Immunoglobulin (CANCUN)CompletedNCT03716700
• Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global)CompletedNCT02593188
• Immune Globulin Subcutaenous (Human), 20%CompletedNCT01412385Phase 2/3
• Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV SubcutaneouslyCompletedNCT00782106Phase 1/2
• Safety, Pharmacokinetic and Efficacy Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Patients With Primary Immunodeficiency (Hypo- or Agammaglobulinemia)CompletedNCT00161993Phase 2
• Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency DisordersCompletedNCT00157079Phase 3